Shanghai Stock Exchange B shares Index

Index

CSEIB

Market Closed - Monde 03:20:00 2024-06-21 EDT 5-day change 1st Jan Change
230.3 PTS -1.48% Intraday chart for Shanghai Stock Exchange B shares Index -2.84% -0.56%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
China Urges Britain Not to Sanction Chinese Companies Over Links to Russia MT
Rightway Holdings to Delist From Shanghai Bourse on June 27 MT
China's Natural Gas Policy Updates to Apply From Aug. 1 MT
Two Chinese Asset Managers to Launch Country's Saudi-Related ETFs MT
China to Levy Provisional Tariffs on EU Pork MT
China's Non-Financial Outbound Direct Investment Jumps 16% in First Five Months of 2024 MT
Chinese NEV Market Penetration Rate Seen to Rise to Record High in June MT
Local Government in China Urged to Buy Completed Commercial Houses MT
China Grand Automotive Services Group Faces Delisting MT
GCL Co-CEO See Little Chance of Silicon Prices Rebound in 2024 MT
Chinese Stocks Dip Amid Weaker Renminbi, Geopolitical Woes; China Grand Automotive Services Drop 10% MT
US Treasury Secretary Yellen Sees Biden's China Tariff Strategic, Trump's Tariffs to Raise Prices MT
Chinese EV Makers Received Upto $231 Billion in Government Subsidies in 15 Years MT
Malaysia, China Inks Deals Worth Over $13 Billion MT
Fudan Zhangjiang Bio-Pharmaceutical Enrolls First Patient for Glioma Drug Trial MT
Pudong Construction, Subsidiaries Bag 1.87 Billion Yuan Worth of Projects MT
China's Banking Watchdog Sets Deadline for Small Banks to Set Up Wealth Management Subsidiaries MT
United Hydrogen Group Seeks Nasdaq Listing Via Blank-Check Merger MT
CNOOC Names Chief Financial Officer MT
Assets of China's Financial Institutions Rise 8.5% as of End-Q1 MT
Yonz Technology Targets 1.4 Billion Yuan From Shanghai IPO MT
Nasdaq Screens More Small-Scale IPOs from Hong Kong, China MT
France Grants Marketing Approval for Huiyu Pharma's Osteoporosis Injection MT
Shanghai Sheng Jian Environment Technology to Change Name MT
Nucien Pharma Completes Phase 2 Trials for Influenza Drug MT